Benno Therapeutics

Benno Tx is developing an innovative immunotherapy targeting the tumor vasculature. Its vaccine against extracellular vimentin showed promising results in a phase 1/2 study, doubling survival in dogs with urothelial carcinoma (374 vs. 196 days, p<0.01) compared to chemotherapy. The IM-administered vaccine is safe, effective, and easy for general practitioners to use. This platform technology is expanding to other cancer types such as osteosarcoma and is expandable to other species, offering a scalable, affordable, and resistance-preventing cancer treatment. With strong PoC data, Benno Tx is advancing veterinary oncology with a first-in-class, targeted immunotherapy that has the potential to revolutionize cancer treatment in pets.